Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG286 vs Components in Glaucoma/OHT
NCT01789736Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2013
- Primary completion
- Jun 2013
- Countries
- 1
- Sponsor
- Aerie Pharmaceuticals
- Modality
- Small Molecules
- Drugs
- verosudil
- Conditions
- open-angle glaucoma (OAG)ocular hypertension
01
Overview
Phase 2, randomised, double-blind trial of verosudil in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by Aerie Pharmaceuticals. Primary endpoint: Mean Diurnal Intraocular Pressure at 28 days. Started Feb 2013; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
PG286
PG286 Ophthalmic Solution 0.5% q.d. O.U.
Verosudil
AR-12286 Ophthalmic Solution 0.5% q.d. O.U.
Travoprost
Travoprost 0.004% q.d. O.U.
03
Who it enrols
Adult patients with open-angle glaucoma or ocular hypertension, unmedicated IOP >= 22 mmHg, and no history of angle closure or severe ocular disease.
04
Endpoints
Primary
Mean Diurnal Intraocular Pressure
Secondary
Intraocular Pressure
Beyond the preview
Go deeper on NCT01789736.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01789736.